QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
NASDAQ:ALLK

Allakos (ALLK) Stock Price, News & Analysis

$1.26
-0.02 (-1.17%)
(As of 02:56 PM ET)
Today's Range
$1.26
$1.32
50-Day Range
$1.09
$1.64
52-Week Range
$1.00
$5.64
Volume
382,203 shs
Average Volume
1.51 million shs
Market Capitalization
$111.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.83

Allakos MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
40.5% Upside
$1.83 Price Target
Short Interest
Bearish
6.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.26mentions of Allakos in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.16) to ($0.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.34 out of 5 stars

Medical Sector

121st out of 939 stocks

Pharmaceutical Preparations Industry

47th out of 433 stocks

ALLK stock logo

About Allakos Stock (NASDAQ:ALLK)

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.

ALLK Stock Price History

ALLK Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program
Allakos Inc. (NASDAQ:ALLK) Sees Large Growth in Short Interest
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
TD Cowen Remains a Hold on Allakos (ALLK)
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
ALLK Sep 2024 2.000 call
ALLK Sep 2024 2.500 call
ALLK Mar 2024 1.500 call
Allakos price target lowered by 50c at Barclays, here's why
Allakos just downgraded at Cantor Fitzgerald, here's why
Allakos just downgraded at LifeSci Capital, here's why
Why Is Allakos (ALLK) Stock Down 57% Today?
See More Headlines
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2023
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
123
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.83
High Stock Price Target
$3.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+43.2%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-185,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.93 per share

Miscellaneous

Free Float
63,208,000
Market Cap
$112.47 million
Optionable
Optionable
Beta
0.83
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Robert Alexander Ph.D. (Age 54)
    CEO & Director
    Comp: $1.46M
  • Dr. Adam L. Tomasi Ph.D. (Age 54)
    President
    Comp: $1.11M
  • Mr. Baird Radford III (Age 54)
    Chief Financial Officer
    Comp: $708.26k
  • Ms. Mary Cromwell Ph.D.
    Chief Technical Officer
  • Dr. Chin Lee M.D. (Age 53)
    M.P.H., Chief Medical Officer
  • Mr. Alan Chang
    Director of Medical Affairs & Data Analytics

ALLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings
or view top-rated stocks.

What is Allakos' stock price target for 2024?

5 brokers have issued 12-month price objectives for Allakos' shares. Their ALLK share price targets range from $1.00 to $3.00. On average, they expect the company's stock price to reach $1.83 in the next twelve months. This suggests a possible upside of 40.5% from the stock's current price.
View analysts price targets for ALLK
or view top-rated stocks among Wall Street analysts.

How have ALLK shares performed in 2024?

Allakos' stock was trading at $2.73 at the beginning of the year. Since then, ALLK stock has decreased by 52.2% and is now trading at $1.3050.
View the best growth stocks for 2024 here
.

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ALLK earnings forecast
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) announced its earnings results on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49).

What ETF holds Allakos' stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 22,191 shares of ALLK stock, representing 1.04% of its portfolio.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

Allakos (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Who are Allakos' major shareholders?

Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.05%), Price T Rowe Associates Inc. MD (9.05%), Vanguard Group Inc. (3.72%), Vanguard Group Inc. (3.72%), Vontobel Holding Ltd. (0.86%) and Sectoral Asset Management Inc. (0.86%). Insiders that own company stock include Adam Tomasi, Henrik S Md Rasmussen, Paul Edward Walker, Robert Alexander and Steven P James.
View institutional ownership trends
.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALLK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners